Genmab — Oktober 2017
-
Jeg er blank på det område Aabforever. Har intet hørt om det.
-
Peter Panik.. Derer vist ingen her i chatten som maler F .. på væggen pga tallene. Det var udlandet som solgte massivt ud i dag.
-
infusionstiden kan jeg ikke forestille mig har noget at sige ifht valg af behandlingsregime. det er patienterne for syge til
-
Men kunne det være forklaring på at salget ROW næsten står stille. At Europa ser mere på cost/benefit?
-
Der er jo en grund til at NICE ikke har godkendt?
-
NICE har ikke godkendt, da de mener at 32% ORR ikke er tilstrækkeligt ifht omkostningen
-
Q&A er d. 9. november kl. 16.
-
Kan det være problemer med at producere nok?? og har det noget med EL notat 17:18
-
Der kan heller ikke være meget gang i combobehandlingerne endnu. Jeg ville have troet, at launchen ville forløbe hurtigere
-
European number, of course, great growth, $54 million in Q1, while the rest of world sales jumping to $87 million. So a really nice sort of 60% increase in Q2 versus Q1, which is great news. Majority of sales is still coming, and it's really driven by 2 countries, Germany and France. And those 2 combined are supplying slightly more than half of the rest of world sales at this point
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind